Cardiac monitoring

DEVICE5 trials

Sponsors

University of Foggia, University Hospital, Strasbourg, France, University of Oxford, ZBeats INC

Conditions

Anxiety StateArrhythmias, CardiacAtrial FibrillationAtrial Fibrillation New OnsetNew Onset Atrial FibrillationParkinson Disease

Phase 2

Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

CompletedNCT03947216

University Hospital, Strasbourg, FranceParkinson Disease

Start: 2020-10-23End: 2024-06-17Updated: 2026-03-16

Unknown Phase

Preoperative Anxiety and Music Therapy

CompletedNCT03171753

University of FoggiaAnxiety State

Start: 2016-02-15End: 2017-06-30Updated: 2017-09-18

Tracking Atrial Fibrillation After Intensive Care Admission

RecruitingNCT05229211

University of OxfordAtrial Fibrillation, Atrial Fibrillation New Onset, New Onset Atrial Fibrillation

Start: 2022-02-01End: 2025-12-30Target: 100Updated: 2024-06-17

Artificial Intelligence (AI) Enabled, Cloud-based ECG Diagnostic Solution (ZBPro) Feasibility Testing

ZBeats INCArrhythmias, Cardiac

Start: 2023-08-30End: 2024-05-31Target: 75Updated: 2023-09-26

Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

Not yet recruitingNCT06754553

University Hospital, Strasbourg, FranceParkinson Disease

Start: 2025-02-28End: 2026-02-28Target: 100Updated: 2025-01-01